Retrospective study of AL-amyloid patients with t(11;14) treated with daratumumab

The standard of care for AL amyloidosis, in patients who are not candidates for a stem cell transplant, is based on Bortezomib-based chemotherapy. Unfortunately, patients harboring the t(11;14), who represent up to 50% of AL amyloidosis cases, have a poor response to Bortezomib. Daratumumab (Dara), a monoclonal antibody targeting CD38 approved for the treatment of patients for multiple myeloma, has been shown to be highly active in heavily pretreated patients with AL amyloidosis (Kaufman et al, Blood 2017).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research